Ascentage Pharma Group International (HK:6855) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Ascentage Pharma Group International excitedly reports on the anticipated presentation of their latest clinical study results for three leading drug candidates at the 2024 American Society of Clinical Oncology Annual Meeting. These drugs include the China-approved olverembatinib and other investigational treatments targeting various cancers. The findings will be shared through oral reports and poster presentations, highlighting the company’s advancements in oncology.
For further insights into HK:6855 stock, check out TipRanks’ Stock Analysis page.